Development of CRISPR as a prophylactic strategy to combat novel coronavirus and influenza

The outbreak of the coronavirus disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), has infected more than 100,000 people worldwide with over 3,000 deaths since December 2019. There is no cure for COVID-19 and the vaccine development is estimated to require 12-18 months. Here we demonstrate a CRISPR-Cas13-based strategy, PAC-MAN (Prophylactic Antiviral CRISPR in huMAN cells), for viral inhibition that can effectively degrade SARS-CoV-2 sequences and live influenza A virus (IAV) genome in human lung epithelial cells. We designed and screened a group of CRISPR RNAs (crRNAs) targeting conserved viral regions and identified functional crRNAs for cleaving SARS-CoV-2. The approach is effective in reducing respiratory cell viral replication for H1N1 IAV. Our bioinformatic analysis showed a group of only six crRNAs can target more than 90% of all coronaviruses. The PAC-MAN approach is potentially a rapidly implementable pan-coronavirus strategy to deal with emerging pandemic strains.

[1]  Su Han,et al.  Molecular Identification and Phylogenetic Analysis of Nuclear rDNA Sequences of Clonorchis sinensis Isolates From Human Fecal Samples in Heilongjiang Province, China , 2019, Front. Microbiol..

[2]  S. Konermann,et al.  Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors , 2018, Cell.

[3]  N. Heaton,et al.  A CRISPR Activation Screen Identifies a Pan-avian Influenza Virus Inhibitory Host Factor. , 2017, Cell reports.

[4]  Bhupal Singh.  Influenza , 1916, Nature Reviews Disease Primers.

[5]  Xiang Li,et al.  On the origin and continuing evolution of SARS-CoV-2 , 2020, National science review.

[6]  Z. Memish,et al.  Middle East Respiratory Syndrome Coronavirus (MERS-CoV) origin and animal reservoir , 2016, Virology Journal.

[7]  Yifan Rao,et al.  The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines. , 2020, NPJ vaccines.

[8]  A Flahault,et al.  Influenza vaccine: the challenge of antigenic drift. , 2007, Vaccine.

[9]  James J. Collins,et al.  Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6 , 2018, Science.

[10]  G. Carmichael,et al.  Dynamic Imaging of RNA in Living Cells by CRISPR-Cas13 Systems. , 2019, Molecular cell.

[11]  H. Feldmann,et al.  Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection , 2020, Proceedings of the National Academy of Sciences.

[12]  Sergey A. Shmakov,et al.  Cas13b is a Type VI-B CRISPR-associated RNA-Guided RNase differentially regulated by accessory proteins Csx27 and Csx28 , 2016, bioRxiv.

[13]  Yoshihiro Kawaoka,et al.  Single-Reaction Genomic Amplification Accelerates Sequencing and Vaccine Production for Classical and Swine Origin Human Influenza A Viruses , 2009, Journal of Virology.

[14]  Israel Steinfeld,et al.  Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells , 2015, Nature Biotechnology.

[15]  Zhìhóng Hú,et al.  A review of studies on animal reservoirs of the SARS coronavirus , 2007, Virus Research.

[16]  P. Palese,et al.  The 3' and 5'-terminal sequences of influenza A, B and C virus RNA segments are highly conserved and show partial inverted complementarity. , 1980, Gene.

[17]  Hideo Goto,et al.  Selective incorporation of influenza virus RNA segments into virions , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Aviv Regev,et al.  Nucleic acid detection with CRISPR-Cas13a/C2c2 , 2017, Science.

[19]  Shibo Jiang,et al.  The spike protein of SARS-CoV — a target for vaccine and therapeutic development , 2009, Nature Reviews Microbiology.

[20]  J. Skehel,et al.  Nucleotide sequences at the 5' termini of influenza virus RNAs and their transcripts. , 1978, Nucleic acids research.

[21]  Yifan Rao,et al.  The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines , 2020, npj Vaccines.

[22]  Y. Liu,et al.  Durable multitransgene expression in vivo using systemic, nonviral DNA delivery , 2019, Science Advances.

[23]  Jonathan H. Epstein,et al.  Bats Are Natural Reservoirs of SARS-Like Coronaviruses , 2005, Science.

[24]  Steven F. Baker,et al.  Replication-Competent Influenza A Viruses Expressing Reporter Genes , 2016, Viruses.

[25]  K. To,et al.  Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan , 2020, Emerging microbes & infections.

[26]  R. Rappuoli.  Glycoconjugate vaccines: Principles and mechanisms , 2018, Science Translational Medicine.

[27]  G. Stepanov,et al.  Systems of Delivery of CRISPR/Cas9 Ribonucleoprotein Complexes for Genome Editing , 2019, Russian Journal of Bioorganic Chemistry.

[28]  Hayden C. Metsky,et al.  Programmable Inhibition and Detection of RNA Viruses Using Cas13. , 2019, Molecular cell.

[29]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[30]  F. DiMeco,et al.  Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy , 2018, Science Translational Medicine.

[31]  Yukiko Muramoto,et al.  Hierarchy among Viral RNA (vRNA) Segments in Their Role in vRNA Incorporation into Influenza A Virions , 2006, Journal of Virology.

[32]  Joy Y. Feng,et al.  The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus , 2020, The Journal of Biological Chemistry.

[33]  Kira S. Makarova,et al.  Cas13d is a compact RNA-targeting type VI CRISPR effector positively modulated by a WYL domain-containing accessory protein , 2018, Molecular cell.

[34]  S. Kutluay,et al.  Nucleotide resolution mapping of influenza A virus nucleoprotein-RNA interactions reveals RNA features required for replication , 2018, Nature Communications.

[35]  Michael W. Davidson,et al.  A bright monomeric green fluorescent protein derived from Branchiostoma lanceolatum , 2013, Nature Methods.

[36]  B. Fielding,et al.  The Coronavirus Nucleocapsid Is a Multifunctional Protein , 2014, Viruses.

[37]  N. Heaton,et al.  Rationally Designed Influenza Virus Vaccines That Are Antigenically Stable during Growth in Eggs , 2017, mBio.

[38]  T. Robinson,et al.  Raising the flag on marine alien fouling species , 2017 .

[39]  Lin Liu.  Fields Virology, 6th Edition , 2014 .

[40]  Hari Shroff,et al.  Influenza A Virus Assembly Intermediates Fuse in the Cytoplasm , 2014, PLoS pathogens.

[41]  L. Brown,et al.  Influenza Virus Neuraminidase Structure and Functions , 2019, Front. Microbiol..

[42]  Zhen Gu,et al.  Rational designs of in vivo CRISPR-Cas delivery systems. , 2019, Advanced drug delivery reviews.

[43]  William A. Lee,et al.  Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys , 2016, Nature.

[44]  D. Hasselquist,et al.  No evidence that carotenoid pigments boost either immune or antioxidant defenses in a songbird , 2018, Nature Communications.

[45]  C. Isel,et al.  Selective packaging of the influenza A genome and consequences for genetic reassortment. , 2014, Trends in microbiology.

[46]  E. Holmes,et al.  A new coronavirus associated with human respiratory disease in China , 2020, Nature.

[47]  Jianwei Wang,et al.  Innate Immunity Evasion by Enteroviruses: Insights into Virus-Host Interaction , 2016, Viruses.

[48]  Baoju Wang,et al.  Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS‐CoV, MERS‐CoV, and 2019‐nCoV , 2020, Journal of medical virology.

[49]  P. Tappenden,et al.  Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review. , 2011, The Journal of infection.

[50]  Lei S. Qi,et al.  CRISPR-mediated live imaging of genome editing and transcription , 2019, Science.